Form 4: Stoke Therapeutics CEO Receives Major Equity Grant

Stoke Therapeutics CEO Ian F. Smith was granted 950,000 equity awards, including stock options and restricted stock units, aligning his interests with long-term shareholder value.

Summary

• Ian F. Smith, Chief Executive Officer and Director of Stoke Therapeutics, Inc. (STOK), was granted derivative securities on October 8, 2025.
• The awards include 570,000 stock options with an exercise price of $30.5 per share and an expiration date of October 7, 2035.
• These stock options will vest as to 1/4 of the total award on October 6, 2026, with an additional 1/48 vesting monthly thereafter, contingent on continued service.
• Additionally, 380,000 Restricted Stock Units (RSUs) were granted, which represent a contingent right to receive one share of common stock upon settlement, with an expiration date of October 6, 2029.
• The RSUs will vest as to 1/4 of the total award annually on October 6, with the first tranche vesting on October 6, 2026, subject to continued service.
• All transactions were made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading strategy.

Sentiment

Score: 6

Explanation: The filing reports a routine grant of equity awards to the CEO, which is a standard compensation practice. It is slightly positive as it aligns management's interests with shareholders, but does not contain information that would significantly alter the company's outlook.

Positives

• The grant of significant equity awards to the CEO aligns management's long-term interests with those of shareholders, incentivizing stock price appreciation.
• The use of a Rule 10b5-1(c) plan indicates a pre-arranged, systematic approach to equity transactions, which is often viewed favorably for transparency and mitigating concerns about insider trading.

Risks

• The value of the granted stock options and restricted stock units is directly tied to the future performance of Stoke Therapeutics' common stock, exposing the CEO to market risk.
• Future exercise of options and settlement of RSUs will result in dilution for existing shareholders, increasing the total number of outstanding shares.

Industry Context

Equity grants, including stock options and restricted stock units, are a standard component of executive compensation packages across the biotechnology and pharmaceutical industries. These awards are typically designed to attract, retain, and incentivize key management personnel by aligning their financial interests with the long-term performance of the company's stock.

Comparison to Industry Standards

• The practice of granting equity awards to executive officers is a common compensation strategy within the biotech sector, aiming to link executive performance with shareholder returns.
• The specific size and vesting schedules of these grants are generally benchmarked against peer companies of similar market capitalization and stage of development, though no specific comparable companies or projects are detailed in this filing.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased alignment of management's long-term interests with shareholder value; however, future exercise and settlement of these awards will lead to dilution of existing shares.
• Employees: The CEO's compensation structure, heavily weighted towards equity, may influence overall compensation philosophy and incentive structures within the company.

Next Steps

• Continued vesting of stock options and restricted stock units according to their respective schedules, contingent on the reporting person's continued service to the Issuer.

Key Dates

Keywords

Stoke Therapeutics, STOK, Form 4, equity awards, stock options, restricted stock units, CEO compensation, insider transaction, Rule 10b5-1 plan